Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study

OBJECTIVE: There is limited experience regarding the use of biological disease-modifying antirheumatic drug (bDMARD) and JAK inhibitor (JAKi) for the management of immune checkpoint inhibitors (ICI)-induced inflammatory arthritis. We aimed to assess their efficacy and safety in this setting. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: De La Fuente, Fanny, Belkhir, Rakiba, Henry, Julien, Nguyen, Chi Duc, Pham, Thao, Germain, Vincent, Gavand, Pierre Edouard, Labadie, Céline, Briere, Claire, Lauret, Ambre, Cardon, Thierry, Mouterde, Gael, Bonnet, Isabelle, Rouxel, Léa, Truchetet, Marie-Elise, Schaeverbeke, Thierry, Richez, Christophe, Kostine, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Miscellaneous
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594531/
https://www.ncbi.nlm.nih.gov/pubmed/36270747
http://dx.doi.org/10.1136/rmdopen-2022-002612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594531/
https://www.ncbi.nlm.nih.gov/pubmed/36270747
http://dx.doi.org/10.1136/rmdopen-2022-002612

Ejemplares similares